US 12,227,556 B2
Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods
Gisela Schimmack, Tuebingen (DE); Annika Sonntag, Tuebingen (DE); Heiko Schuster, Tuebingen (DE); Daniel Johannes Kowalewski, Tuebingen (DE); Michael Roemer, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Toni Weinschenk, Tuebingen (DE); and Harpreet Singh, Tuebingen (DE)
Assigned to Immatics Biotechnologies GmbH, Tübingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Sep. 24, 2021, as Appl. No. 17/484,721.
Application 17/484,721 is a continuation of application No. 16/717,142, filed on Dec. 17, 2019, granted, now 11,779,605.
Claims priority of provisional application 62/884,507, filed on Aug. 8, 2019.
Claims priority of provisional application 62/781,342, filed on Dec. 18, 2018.
Claims priority of application No. 10 2018 132 617.3 (DE), filed on Dec. 18, 2018.
Prior Publication US 2022/0008472 A1, Jan. 13, 2022
Int. Cl. A61K 38/00 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 14/73 (2006.01); C07K 14/74 (2006.01); C07K 16/00 (2006.01); C12N 5/0783 (2010.01); C07K 7/00 (2006.01)
CPC C07K 14/70514 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/001186 (2018.08); C07K 14/70517 (2013.01); C07K 14/70539 (2013.01); C07K 16/00 (2013.01); C12N 5/0636 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/605 (2013.01); C07K 7/00 (2013.01)] 17 Claims
 
1. An isolated peptide consisting of the amino acid sequence YVYANHFTEA (SEQ ID NO: 291) in the form of a pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.